Morgan Stanley Forecasts Strong Price Appreciation for REGENXBIO (NASDAQ:RGNX) Stock
REGENXBIO (NASDAQ:RGNX – Free Report) had its price objective raised by Morgan Stanley from $22.00 to $24.00 in a research report report published on Friday,Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock. Several other research firms also recently commented on RGNX. StockNews.com raised REGENXBIO from a “sell” rating to […]
